Comparative Pharmacology
Head-to-head clinical analysis: MD 76 versus ORAGRAFIN SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MD 76 versus ORAGRAFIN SODIUM.
MD-76 vs ORAGRAFIN SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
MD-76 is a contrast agent that contains iodine, which attenuates X-rays, thereby enhancing the contrast between vascular structures and surrounding tissues. It distributes in the extracellular fluid compartment and is excreted unchanged by glomerular filtration.
Oragrafin Sodium is an oral cholecystographic contrast agent containing sodium ipodate. It is absorbed orally, excreted by the liver into bile, and concentrates in the gallbladder, allowing radiographic visualization. The iodine atoms in the molecule absorb X-rays, providing contrast. It also inhibits thyroid hormone synthesis by blocking iodine organification and may be used in amiodarone-induced thyrotoxicosis.
IV: 50-100 mL per dose, administered as a bolus or infusion, not to exceed 3 mL/kg total dose.
Oral: 50-60 mL of a 10% solution (5-6 g sodium iopodate) as a single dose 10-12 hours before cholecystography. Repeat if needed: 50 mL (5 g) the next evening. Intravenous: Not applicable (oral agent).
None Documented
None Documented
Terminal half-life: 1.5–2 hours; prolonged in renal impairment (up to 20 hours in anuria); clinical context: allows rapid elimination, suitable for diagnostic imaging
Terminal elimination half-life is approximately 60-90 minutes in patients with normal renal function (creatinine clearance > 90 mL/min), reflecting rapid renal clearance of this water-soluble contrast agent.
Renal: >95% unchanged via glomerular filtration; biliary/fecal: <5%
Primarily renal (hepatic/biliary/fecal: minimal). Approximately 80-90% of the absorbed dose is excreted unchanged in urine via glomerular filtration; <10% eliminated in feces via biliary excretion.
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent